Sarah A. Holstein

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 653 citations · Full text

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2017 · 277 citations · Full text

Hematological Malignancy, Plasma Cells, Bone Marrow Failure +14

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2018 · 203 citations · Full text

Hematological Malignancy, Medicine, Hematology +10

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Sarah A. Holstein, Sin‐Ho Jung, Paul G. Richardson et al. · The Lancet Haematology · 2017 · 168 citations · Full text

Hematological Malignancy, Oncology, Marrow Transplantation +10

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Sergio Giralt, Laurent Garderet, Brian G.M. Durie et al. · Biology of Blood and Marrow Transplantation · 2015 · 162 citations · Full text